Download PDF
Semin Thromb Hemost 2018; 44(01): 007-011
DOI: 10.1055/s-0037-1608798
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Complications of Implanted Nonbiologic Devices—An Overview

Hau C. Kwaan
1   Division of Hematology-Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
› Author Affiliations
Further Information

Publication History

Publication Date:
24 November 2017 (online)

    Permissions and Reprints

Abstract

Under physiologic conditions, blood is contained within the vascular space lined with smooth endothelial cells. When various devices made of nonbiologic material are implanted, blood will be exposed to a foreign surface. A series of events ensue and may lead to many complications, including thrombosis, hemolysis, thrombocytopenia, bleeding, infection, and malfunction of the device. The incidence, manifestations, and special characteristics of these complications vary with different types of implanted devices. However, they have in common an important pathogenic pathway that of an exposure to a foreign surface. Despite the development of improved versions of these devices, more research on the causative factors of these complications is needed to take preventive and corrective measures, particularly those that enhance the process of healing by re-endothelialization of the foreign surface. This article is a brief review of the complications encountered in blood-contacting devices.

Keywords

biomaterial - implanted devices - thrombosis - endothelial cells - thrombocytopenia
 

  • References

  • 1 Hale S. Experiment 3; statistical essays: containing haemostatics. In: White PD. , ed. Heart Disease, 3rd ed. New York, NY: MacMillan; 1974: 74
    Google Scholar
  • 2 Kalso E. A short history of central venous catheterization. Acta Anaesthesiol Scand Suppl 1985; 81: 7-10
    PubMedGoogle Scholar
  • 3 Kirkup J. Surgical history. The history and evolution of surgical instruments. VIII. Catheters, hollow needles and other tubular instruments. Ann R Coll Surg Engl 1998; 80 (02) 81-90
    PubMedGoogle Scholar
  • 4 Vroman L, Adams AL. Identification of rapid changes at plasma-solid interfaces. J Biomed Mater Res 1969; 3 (01) 43-67
    CrossrefPubMedGoogle Scholar
  • 5 Vroman L, Adams AL, Fischer GC, Munoz PC. Interaction of high molecular weight kininogen, factor XII, and fibrinogen in plasma at interfaces. Blood 1980; 55 (01) 156-159
    CrossrefPubMedGoogle Scholar
  • 6 Hirsh SL, McKenzie DR, Nosworthy NJ, Denman JA, Sezerman OU, Bilek MM. The Vroman effect: competitive protein exchange with dynamic multilayer protein aggregates. Colloids Surf B Biointerfaces 2013; 103: 395-404
    CrossrefPubMedGoogle Scholar
  • 7 Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 2004; 25 (26) 5681-5703
    CrossrefPubMedGoogle Scholar
  • 8 Turbill P, Beugeling T, Poot AA. Proteins involved in the Vroman effect during exposure of human blood plasma to glass and polyethylene. Biomaterials 1996; 17 (13) 1279-1287
    CrossrefPubMedGoogle Scholar
  • 9 Jaffer IH, Fredenburgh JC, Hirsh J, Weitz JI. Medical device-induced thrombosis: what causes it and how can we prevent it?. J Thromb Haemost 2015; 13 (Suppl. 01) S72-S81
    CrossrefPubMedGoogle Scholar
  • 10 Cohen HC, Joyce EJ, Kao WJ. Biomaterials selectively modulate interactions between human blood-derived polymorphonuclear leukocytes and monocytes. Am J Pathol 2013; 182 (06) 2180-2190
    CrossrefPubMedGoogle Scholar
  • 11 Savage B, Ruggeri ZM. Selective recognition of adhesive sites in surface-bound fibrinogen by glycoprotein IIb-IIIa on nonactivated platelets. J Biol Chem 1991; 266 (17) 11227-11233
    PubMedGoogle Scholar
  • 12 Reejhsinghani R, Lotfi AS. Prevention of stent thrombosis: challenges and solutions. Vasc Health Risk Manag 2015; 11: 93-106
    PubMedGoogle Scholar
  • 13 Gorbet MB, Sefton MV. Material-induced tissue factor expression but not CD11b upregulation depends on the presence of platelets. J Biomed Mater Res A 2003; 67 (03) 792-800
    PubMedGoogle Scholar
  • 14 Brancati MF, Burzotta F, Trani C, Leonzi O, Cuccia C, Crea F. Coronary stents and vascular response to implantation: literature review. Pragmat Obs Res 2017; 8: 137-148
    PubMedGoogle Scholar
  • 15 Nakazawa G, Otsuka F, Nakano M. , et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57 (11) 1314-1322
    CrossrefPubMedGoogle Scholar
  • 16 Sata M, Saiura A, Kunisato A. , et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8 (04) 403-409
    CrossrefPubMedGoogle Scholar
  • 17 Caplice NM, Bunch TJ, Stalboerger PG. , et al. Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc Natl Acad Sci U S A 2003; 100 (08) 4754-4759
    CrossrefPubMedGoogle Scholar
  • 18 Granada JF, Price MJ, French PA. , et al. Platelet-mediated thrombosis and drug-eluting stents. Circ Cardiovasc Interv 2011; 4 (06) 629-637
    CrossrefPubMedGoogle Scholar
  • 19 Stefanini GG, Holmes Jr DR. Drug-eluting coronary-artery stents. N Engl J Med 2013; 368 (03) 254-265
    CrossrefPubMedGoogle Scholar
  • 20 Henry JJD, Yu J, Wang A, Lee R, Fang J, Li S. Engineering the mechanical and biological properties of nanofibrous vascular grafts for in situ vascular tissue engineering. Biofabrication 2017; 9 (03) 035007
    CrossrefPubMedGoogle Scholar
  • 21 Bull BS, Rubenberg ML, Dacie JV, Brain MC. Red-blood-cell fragmentation in microangiopathic haemolytic anaemia: in-vitro studies. Lancet 1967; 2 (7526): 1123-1125
    PubMedGoogle Scholar
  • 22 Hasin T, Deo S, Maleszewski JJ. , et al. The role of medical management for acute intravascular hemolysis in patients supported on axial flow LVAD. ASAIO J 2014; 60 (01) 9-14
    CrossrefPubMedGoogle Scholar
  • 23 Katz JN, Jensen BC, Chang PP, Myers SL, Pagani FD, Kirklin JK. A multicenter analysis of clinical hemolysis in patients supported with durable, long-term left ventricular assist device therapy. J Heart Lung Transplant 2015; 34 (05) 701-709
    CrossrefPubMedGoogle Scholar
  • 24 Koliopoulou A, McKellar SH, Rondina M, Selzman CH. Bleeding and thrombosis in chronic ventricular assist device therapy: focus on platelets. Curr Opin Cardiol 2016; 31 (03) 299-307
    CrossrefPubMedGoogle Scholar
  • 25 Reich HJ, Morgan J, Arabia F. , et al. Comparative analysis of von Willebrand factor profiles after implantation of left ventricular assist device and total artificial heart. J Thromb Haemost 2017; 15 (08) 1620-1624
    CrossrefPubMedGoogle Scholar
  • 26 Reininger AJ. The function of ultra-large von Willebrand factor multimers in high shear flow controlled by ADAMTS13. Hamostaseologie 2015; 35 (03) 225-233
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Moake JL. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Hematol 2004; 41 (01) 4-14
    CrossrefPubMedGoogle Scholar
  • 28 Pottinger BE, Read RC, Paleolog EM, Higgins PG, Pearson JD. von Willebrand factor is an acute phase reactant in man. Thromb Res 1989; 53 (04) 387-394
    CrossrefPubMedGoogle Scholar
  • 29 Klovaite J, Gustafsson F, Mortensen SA, Sander K, Nielsen LB. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol 2009; 53 (23) 2162-2167
    CrossrefPubMedGoogle Scholar
  • 30 Nascimbene A, Neelamegham S, Frazier OH, Moake JL, Dong JF. Acquired von Willebrand syndrome associated with left ventricular assist device. Blood 2016; 127 (25) 3133-3141
    CrossrefPubMedGoogle Scholar
  • 31 Cushing K, Kushnir V. Gastrointestinal bleeding following LVAD placement from top to bottom. Dig Dis Sci 2016; 61 (06) 1440-1447
    CrossrefPubMedGoogle Scholar
  • 32 Francolini I, Vuotto C, Piozzi A, Donelli G. Antifouling and antimicrobial biomaterials: an overview. APMIS 2017; 125 (04) 392-417
    CrossrefPubMedGoogle Scholar
  • 33 Baddour LM, Wilson WR, Bayer AS. , et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132 (15) 1435-1486
    CrossrefPubMedGoogle Scholar
  • 34 Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH. Incidence of infective endocarditis in England, 2000-13: a secular trend, interrupted time-series analysis. Lancet 2015; 385 (9974): 1219-1228
    CrossrefPubMedGoogle Scholar
  • 35 Xu Y, Larsen LH, Lorenzen J. , et al. Microbiological diagnosis of device-related biofilm infections. APMIS 2017; 125 (04) 289-303
    CrossrefPubMedGoogle Scholar
  • 36 Gordy S, Rowell S. Vascular air embolism. Int J Crit Illn Inj Sci 2013; 3 (01) 73-76
    CrossrefPubMedGoogle Scholar
  • 37 McCarthy CJ, Behravesh S, Naidu SG, Oklu R. Air embolism: diagnosis, clinical management and outcomes. Diagnostics (Basel) 2017; 7 (01) 5
    CrossrefPubMedGoogle Scholar
  • 38 Muth CM, Shank ES. Gas embolism. N Engl J Med 2000; 342 (07) 476-482
    CrossrefPubMedGoogle Scholar
  • 39 Wong S, Kwaan HC, Ing TS. Venous air embolism related to the use of central catheters resisted: with emphasis on dialysis catheters. Clin Kidney J 2017; ; 10 DOI: 10.1093/cjk/sfx064.
    PubMedGoogle Scholar
  • 40 Bessereau J, Genotelle N, Chabbaut C. , et al. Long-term outcome of iatrogenic gas embolism. Intensive Care Med 2010; 36 (07) 1180-1187
    CrossrefPubMedGoogle Scholar
  • 41 McCarthy CJ, Behravesh S, Naidu SG, Oklu R. Air embolism: practical tips for prevention and treatment. J Clin Med 2016; 5 (11) E93
    CrossrefPubMedGoogle Scholar
  • 42 Susen S, Rauch A, Van Belle E, Vincentelli A, Lenting PJ. Circulatory support devices: fundamental aspects and clinical management of bleeding and thrombosis. J Thromb Haemost 2015; 13 (10) 1757-1767
    CrossrefPubMedGoogle Scholar
  • 43 Weitz JI. Factor XI and factor XII as targets for new anticoagulants. Thromb Res 2016; 141 (Suppl. 02) S40-S45
    CrossrefPubMedGoogle Scholar
  • 44 Gailani D, Gruber A. Factor XI as a therapeutic target. Arterioscler Thromb Vasc Biol 2016; 36 (07) 1316-1322
    CrossrefPubMedGoogle Scholar
  • 45 Laschke MW, Menger MD. Prevascularization in tissue engineering: current concepts and future directions. Biotechnol Adv 2016; 34 (02) 112-121
    CrossrefPubMedGoogle Scholar